Olaparib
OLAGLI
Hospices Civils de Lyon (OLAGLI) · Phase 2 · Completed · Enrollment 35
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Olaparib 300 mg BID | recurrent IDH-mutant high-grade glioma (n = 35) | 300 mg | Single arm | n/r | 6-month PFS rate: 31.4%, primary endpoint, target 50% not metmedian PFS: 2.05 monthsmedian OS: 15.9 months |